Related Experiment Video
Updated: Jul 2, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Factor VIIa (recombinant) for acute traumatic hemorrhage
1Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, 11213 North Platte Drive, Tucson, AZ 85737, USA. patanwala@pharmacy.arizona.edu
Summary
Recombinant factor VIIa may reduce red blood cell transfusions in blunt traumatic hemorrhage patients. Its effect on mortality in trauma patients is still under investigation.
Area of Science:
- Trauma care
- Hematology
- Pharmacology
Background:
- Uncontrolled hemorrhage in trauma patients can lead to coagulopathy.
- Recombinant factor VIIa (rFVIIa) is a hemostatic agent used for various bleeding conditions.
Purpose of the Study:
- To review the use of rFVIIa for treating acute traumatic hemorrhage.
- To identify randomized controlled trials (RCTs) on rFVIIa in traumatic hemorrhage.
Main Methods:
- Literature review including RCTs, retrospective evaluations, and case series.
- Focused on studies investigating rFVIIa for traumatic hemorrhage treatment.
Main Results:
- One RCT showed reduced red blood cell (RBC) transfusion needs in blunt traumatic hemorrhage with rFVIIa.
- No reduction in RBC transfusion was observed in penetrating trauma patients in another RCT.
- Current trials are not powered to determine mortality differences.
Conclusions:
- rFVIIa may reduce RBC transfusion requirements in blunt traumatic hemorrhage.
- The impact of rFVIIa on mortality in trauma patients remains unknown and is under investigation.
- Consider rFVIIa as an adjunctive therapy only after optimizing other treatments.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:05Introduction to Hemostasis
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...